Stereotaxis

Stereotaxis pioneered robotic magnetic navigation (RMN) technology for cardiac electrophysiology procedures, offering systems installed in over 100 hospitals worldwide and used to treat more than 150,000 patients as of late 2025. The company distributes its products in China through an exclusive partnership with Shanghai MicroPort EP Medtech (688351.SH), established in 2021.

Company Overview

Founded in 1990 by researchers developing magnetic navigation techniques for surgery, Stereotaxis has spent over three decades refining RMN technology for minimally invasive endovascular interventions. The company went public in 2004 and currently trades on the NYSE under the symbol STXS.

Stereotaxis relocated its global headquarters to a 43,000 square-foot facility in the renovated Globe Building in downtown St. Louis in March 2022. In May 2024, the company expanded its manufacturing capabilities by acquiring Access Point Technologies, a catheter developer based in Rogers, Minnesota.

The technology uses adjustable electromagnets to guide and stabilize catheters within the beating heart, providing millimeter-level precision that enables treatment of complex arrhythmias often unreachable with manual techniques. RMN has been validated in over 500 peer-reviewed publications demonstrating safety and efficacy benefits over traditional catheter manipulation.

Core Products

Genesis RMN System

The flagship robotic magnetic navigation platform represents the latest evolution of Stereotaxis technology. Genesis features smaller magnets on flexible robotic arms that provide instantaneous responsiveness to physician control. The system received NMPA approval in November 2024 and is CE marked and FDA cleared.

GenesisX System

A semi-mobile version designed for rapid adoption, GenesisX eliminates the need for room-based magnetic shielding by incorporating shielding into the system structure itself. It operates on standard 120/230V power, requires no structural anchoring, and features an 80% smaller cabinet that fits under operating room tables. GenesisX received CE Mark in 2024 and FDA 510(k) clearance in November 2025.

MAGiC Catheter Family

The Magnetic Interventional Ablation Catheter (MAGiC) represents Stereotaxis’ first proprietary ablation catheter. Designed with increased stability and more intuitive navigation compared to legacy third-party catheters, MAGiC received CE Mark in January 2025 and FDA approval in January 2026 for treating patients with complex congenital heart disease.

MAGiC Sweep

A robotically navigated high-density electrophysiology mapping catheter with 20 electrodes for rapid, detailed electroanatomical mapping. The flexible, atraumatic design avoids anatomic distension caused by rigid catheters. FDA cleared in July 2025.

Technology & Innovation

RMN technology fundamentally transforms catheter movement by allowing physicians to guide catheters from the tip using magnetic fields rather than pushing from the handle through the shaft. Key technical advantages include:

• Precision: 1mm/1° accuracy unmatched by manual manipulation
• Stability: Flexible catheter shaft acts as shock absorber against cardiac motion
• Reach: Magnetic guidance enables navigation through complex anatomical paths
• Safety: Atraumatic catheter tips reduce perforation risk
• Radiation reduction: Remote operation from a protected cockpit reduces physician exposure

The company holds over 100 issued patents supporting its technology platform and continues development across EP and broader vascular applications.

China Market Presence

Stereotaxis entered the Chinese market through a strategic partnership with Shanghai MicroPort EP Medtech, one of China’s leading electrophysiology device companies. The collaboration encompasses:

• Exclusive distribution of Stereotaxis robotic systems and catheters
• Integration with MicroPort EP’s Columbus 3D mapping system
• Joint development and commercialization efforts

The Genesis RMN System received NMPA approval in November 2024, with MicroPort EP initiating commercial launch through its existing EP sales network. The Magbot catheter (a collaborative product) also received Chinese regulatory approval in December 2024.

Key Milestones

• 1990: Company founded in St. Louis
• 2003: First Niobe RMN system launched
• 2004: Initial public offering
• 2019: Genesis RMN system introduced, CE marked
• 2021: Strategic partnership with MicroPort EP established
• 2022: Relocated to new headquarters in downtown St. Louis
• 2024: Access Point Technologies acquired; Genesis NMPA approved; GenesisX CE marked
• 2025: GenesisX FDA cleared; MAGiC catheter CE marked; MAGiC Sweep FDA cleared
• 2026: MAGiC catheter FDA approved

Financial Overview

For fiscal year 2024, Stereotaxis reported total revenue of $26.9 million with a system backlog of $15.2 million entering 2025. The company anticipates double-digit revenue growth in 2025, driven by expanding catheter adoption and GenesisX system sales. Recurring revenue gross margin reached 70% in 2024.

Frequently Asked Questions

What is the difference between Genesis and GenesisX?

Genesis requires dedicated room construction with magnetic shielding built into walls, while GenesisX incorporates shielding into the system itself and can be installed in existing cath labs over a weekend without room modification.

How does Stereotaxis technology differ from manual catheter ablation?

RMN uses magnetic fields to navigate catheters from the tip with millimeter precision, while manual ablation requires physicians to push catheters from the handle. RMN offers greater stability, reduced perforation risk, and enables remote operation that protects physicians from radiation.

Is Stereotaxis available in China?

Yes, the Genesis RMN System received NMPA approval in November 2024 and is distributed exclusively by MicroPort EP Medtech throughout China.